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The initial stages of the interaction of daunomycin (DNM) with drug-sensitive (P388/S) and drug-resistant (P388/100) cells have been defined by 
a rapid kinetics stopped-flow proccdurc. The process cun be described by two kinetic components. The faster component accounts for rapid 
occupation of cell surfidcc sites by DNM, as supported by experiments with liposomes with different surface charge. On the other hand, the em&t 
of vcrapamil n the assays, suggests hat the slower component isinvolved in the transport ofthe drug into the cells. Our observations areconsistent 
with a loss in the control of the ptissivc permeability to the drugs in the drupresistant tumor cells. 
Rapid kinetics: Anthracyclinc resistance; P388 cell 
I. INTRODUCTION 
Reduced intracellular drug accumulation in drug-re- 
sistant umor cells with respect o their parental drug- 
sensitive counterparts constitutes a hallmark of multi- 
drug resistance (MDR) [I-Z]. Thus, alterations in drug 
transport hrough the cell membrane are expected to be 
the basis of the mechanisms of resistance to the anti- 
neoplastics [3]. In this regard, the overexpression of 
P-glycoproteins in drug-resistant cells acting as drug 
efflux pumps represents a well-supported mechanism to 
reduce intracellular drug accumulation in MDR cells 
[4], However, recent reports demonstrate the existence 
of drug-resistant cell lines which do not overexpress 
P-glycoproteins [5,6]. Moreover, in some instances the 
level of expression of P-glycoproteins does not correlate 
with alterations in drug accumulation [7,8]. In murine 
leukemia P388 cells, differences in drug transport and 
efflux between drug-sensitive and drug-resistant cells 
can not be explained exclusively 02 the basis of the 
pump activity of P-glycoproteins [9]. These premises 
support the notion that, in addition to drug efflux medi- 
ated by P-glycoproteins, other membrane transport al- 
terations should be invoked to explain the differences 
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in drug accumulation between drug-sensitive and drug- 
resistant cells. 
Transport of the anti-cancer anthracyclines in tumor 
cells has been difficult to evaluate because of the rapid- 
ity of the process and the enormous extent of intraccllu- 
lar binding of the drugs [IO]. Hence, resistance due to 
decreased intracellular binding might be difficult to dis- 
tinguish from resistance due to decreased rug trans- 
port. In the present study, a rapid kinetics procedure 
has been applied to define the initial steps in the interac- 
tion of the anthracycline DNM with murinc leukemia 
P388 cells, as well as to provide a quantitative stima- 
tion of the possible kinetic differences of such interac- 
tions between daunomycin (DNM)-sensitive and 
DNM-resistant P388 cells. 
2. MATERIALS AND METHODS 
DNM-sensitive P388 murinc leukemia &Is (P388/S) and a 90-100~ 
fold resistant, stable sub-line (P388/100) were grown and maintained 
as described in [I I], 
Fast kinetics mcasuremcnts for the initial interaction of DNM with 
the P388/S and P388/100 cells have bern made using a HiTech 
stopped-flow spectraphotometer (model SF-51) set up in the fiucres- 
ccnce mode and operating with a 150-W xenon lamp. The process was 
initiated by rapidly mixing 0. I ml of a suspension of 2. IO” cellslml in 
IO mM HEPES buffer, pH 7.?. containing I30 mM NaCI. 5 mM KCI, 
I ,8 mM CaCI? and 1 mM MgC& (HBS solution). with an qua1 volume 
of IOpM DNM in the same solution. Experiments in the presenec of 
verapamil (VRP) were done by incubating the cell suspensions with 
5 yM of the drug for 2 h prior to the acquisition of the kinetic traces. 
The samples were excited at 478 nm and fluorescence emission was 
monitored by using a glass OG-530 cutoff filter (50% transmission at 
525 nm). Visual monitoring and storage of the data were obtained by 
using an interfaced Apple He computer. A total of 200 points were 
coiiccted for each trace and fiitcd by a non!inex rpgesslon method 
using the algorithm of Marquardt to quations containing a single 
exponential term: 
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or lhc sum 01’ two cxponentiitlr tcrnis: 
F(f) = .*I, [csp(-k,./)] +/I: [csP(-k:./)] +C’ (2) 
when F(I) is the Huorcsccncc UI time 1. C is 111~ cr~uilihrium Iluarss- 
ceiicc Icvul, .dl,, A: and k,. k:. rcprcscnt the anlplitudcs ilnd lllr! ilppilr- 
cm rate constants. rcspcctivcly, ;tssociatcri \vith rach ol’ lhc tcrins 
cxprcsscd in equations I or 2. Ccl1 viability ut IIIC end cd lhc‘ cxpcri- 
moms wits similar to that ol’ lhr Stilrlitlg sumplcs (>95%). 
Long-tcmr upt:k 01‘ DNM by the P3Y8 cells W;IS curried out ;IS 
described in II?], Brictly. ccl1 suspensions (IO” ccllsin~l) in Hl3S wcrc 
incubutcd with 3 PM solutions 01’ DNM. in the abscncc or in 111~ 
prcscnce ol’ 5 @,I VRP at WC, In the I;tttcr. the’ cells wcrc in the 
presence o1’VRP I’or 2 b bclbrc the addition ol’ DNM. Up011 90 rnin 
ol’incub;~tion, ;Iliquots wcrc rcniovcd and a~~alyzcd by tlow cytometry 
in ;LII Epics Profile I instrunxnt cquippcd with ;I 0.75 W :IQOII litscr. 
set ut 188 nm. The conccntr:Ition ol’ drug associated IO cxh cell is 
proportionul to lhc tncitn Iluorcsccncc intcnsily (IlIWll Iluorcsr.ciise 
chmxl) dwrminud in the histogrms. A total al’ lO.UOt1 cells wcrc 
mcusured during WA s;~mplc ;ui;llysis. Ccl1 viability rcin:lins un;f- 
rected during the ;ISS;I~S (9T5%1, 
Positively (PCL)-. nsutr:& and ncyativcly (NCL) chqcd liposotnss 
wcrc I’rom Avanti Polar Lipids. Neutral liposomcs contain egg 
phosphatidylcholinc (03 ,~mol) and cholcstcrol (9 pmol). The compo- 
sition of PCL ;md NCL liposonxs W;IS tlw smc’ :IS that ol’ ncu trul 
liposomus with. in addition, dicctyl phosph;~tc ( IS q~l) or stcoryl- 
amine (18 pn~l), rcspcctivcly. The prrlpnration ol’thcsc liposomcs has 
been previously &scribed II 31. 
3. RESULTS 
The kinetics of the initial stages for the rapid interac- 
tion between the lipophilic anthracyclinc, DNM, and 
murine leukemia P388 cells has been determined by 
stopped-flow techniques under conditions which pre- 
serve cell viability (~95%). The assay is based up’on the 
change in the fluorescence quantum yield when the drug 
incorporates into hydrophobic environments [14], such 
as those provided by the lipid bilayer of the cell mem- 
branes. This allows for a direct, continuous and rapid 
monitoring of the curly steps of drug association to the 
cells, restricted only by the time required to obtain an 
tidcquate mixing between cells and DNM (-0.1 s). 
Fig. IA shows the continuous recording of the Ruo- 
rescence decays corresponding to the initial interaction 
of 5 PM DNM with the P388/S and P388/100 cells. The 
traces reveal that following a rapid decay during the 
first few seconds upon mixing, there is a slower decrease 
in the fluorescence signal with time. Computer fitting of 
the experimental traces to exponential equations con- 
taining one or more exponential terms, indicates that 
the interaction of DNM with the P38P cells can be 
satisfactorily described by the sum of two exponential 
terms (solid lines in Fig. IA represent fits of the traces 
to equation 2 in Materials and Methods). In fact, addi- 
tion of a third exponential term in equation 2. results 
in neither improvement of the fit nor better statistical 
determinations. giving nonsensical values of the ampli- 
tudes, and was therefore unwarrtinted (not shown). The 
kinetic parameters obtained upon fitting the traces to 
equation 2 arc summarized in Table I. It is observed 
that the two kinetic components contribute significantly 
to the overall process (comparable amplitude values, A I 
and A?, in Tuble I) and that the apparent rate constant 
ii, associated to the faster step is -4015% more rapid in 
the P38WlOO thun in the P388/S cells. On the other 
hand, similar I;, values corresponding LO the apparent 
rate constant oi’ the slower component, were obtained 
for both cell lines (Table I). The two components in the 
double exponential process can be visualized separately 
by computer simulation (based on the kinetic parame- 
ters obtained upon fitting the experimentai recordings 
to equation 2), allowing for an easier comparison of the 
individual steps involved in the inleracGon of DNM 
with the P38WS and P3WlOO cells (Fig. II3 and C. 
respectively). 
The cbservcd total amplitude of the fluorescence 
1500 L I 
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Fig. I. Stopped-Row rccordjngs corresponding to the Huorcscencc dcc;ty 01’ DNM upon rapid mixing with the PfXX cctlr. Final concentrtltion 01 
DNM was 5 PM; final density of cells was I. IO” cells/ml. (A) Conqxrison ol‘ the kinetics 01’ the initiul intcrxtion bctwccn DNM and P388/S (I ) 
and P388/100 (2) ceils. Fits to cquution 2 in Mittcriuls and Methods arc rcprcscntcd by solid lines. (D and C) Individuulired computer simulution 
analysis of the two tcrrns or qualion 2, l&t (B) illId slow (C). corrcspondiny to thr initial interaction of DNM with the P3W.S (I ) und PXWIOO 
(2) cells. 
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Tabk I 
Kinetic pdramctcrs corresponding to the initiul steps in the intcruction 
of DNM with the P388 ceils obtuincd upon fitting ~hu cxpcrimcattll 
traces to cquution 2 yivcn in Matcriuls and Methods 
Pliramuter* P3WS f??88/100 
No I’RP 
/II 868 Ii 52 741 264 
k, 0.856 T 0.235 I.510 5 0.297 
A? 969 2 G 695 t 5 
I& 0.031 2 0.004 0.034 1 0.001 
c 1181 i 8 19ti2 2 7 
I’RP 
A I 856 I IO1 1121 f 71 
1 ‘I I.283 5 0.016 I.299 !z 0.021 
‘42 820 ?: 8 1x3 4 B 
k: 0.037 2 0.001 0.055 + O.OOl 
c 927 r I I 1361 1: 4 
*Dctcrminrtion ol’ thu kinetic pzxmctc’rs in the ~tbscncc (No VW) 
and in ~hc prcscncc (VRP) 01’ 5 PM VRP. rcspcctivcly. 
The vulucs corresponding to the ;miplitudcs 01, ~xl (1:) und to the 
appurcnt rutc COIW~III~S (k, ;~nd k2). i+rc given :I$: tluortixcuncc :lrbitrury 
units und s ’ t S.D.. rcspcctivcly. ()I=(,). 
change sccn~s to bc greater in the P388/S cells than in 
the 1)388/100 cells. This is rcflccted in tcrnl C of equu- 
tion 2, which represents the extrapolated equilibrium 
fluorescence intensity of the reacting system (cells + 
DNM), and which predicts that the association of 
DNM to the P388/S should bc greater than that to the 
P388/100 cells. Such an expectation is in qualitative 
agreement with the results obtained in long-term uptake 
experiments of DNM by the P388 cells using laser flow 
cytometry under steady-state conditions (Fig. 2A). 
It seems reasonable to assume that the faster compo- 
nent in the interaction of DNM with the cells should 
involve cell surface in!cractions. To explore this possi- 
bility, we have analyzed the influence of different sur- 
1 
Fig. 2. Long-term up~kc of DNM by the P3WS cells ( I ) und P388/ 
100 cells (2). in the absence (A) or in the proscnce (B) of 5 PM VRP. 
The Y-axis indicates ~hc normuliecd Ruorcsccncc oi‘ DNM (mean 
fluorescence channel in the histograms) associukd with each ccl1 pop’ 
ulation. 100% rcfcrs to the f?uorescencc of DNM in the P388/S cul!s 
in the absence of VRP. Bxs + S.D. 
fact environments on the kinetics of the association of 
DNM to liposomes having either positive (PCL), neu- 
tral, or negative surface charge (NCL). These experi- 
ments were done at pH 7.2, at which most of the drug 
is present as a cationic foral (p/C, 7.6-8.2 [lo]). Fig. 3 
illustrates the kinetic differences in the interaction be- 
tween DNM and the three types of liposomes. It can be 
observed that the apparent rate constant for the faster 
component follows the sequence: PCL>ncutral>NCL. 
This observation seems consistent with the fact Lhat 
P388/100 cells have a more cationic surface environ- 
ment than the P388/S cells [I I]. thus suggesting that the 
surface charge may play an important role in determin- 
ing the rate at which interaction between DNM and 
cells occurs. 
Solubiliwlion of DNM into the lipid bilayer of the 
cell membranes following drug adsorption onto the cell 
surface is considered the mechanism by which anthracy- 
clincs enter tumor cells, i.e. by passive diffusion [lO,lS]. 
On this basis. we have tentatively ascribed the slower 
step of the interaction of DNM with the cells to a com- 
ponent involved in the passive permeability to the drug. 
The simplest experimental design to measure the rate of 
the diffusion of DNM through the P388 cells implies 
initial conditions in which the drug is present only in the 
cxtraccllulor medium. In this regard. trn added advan- 
tage of using stopped-flow techniques is that, at the 
time scale used in the cxpcriments. the extracellular con- 
centration of DNM should be sufficiently high with 
respect to that inside the cells as to maintain a steep 
gradient hat would favor unidirectional diffusion of the 
drug into the cells. thus making processes such as disso- 
ciation of DNM from cellular targets or drug efflux by 
passive diffusion negligible. Nevertheless. even at low 
concentrations of intracellular drug, the occurrcncc of 
active drug efflux mediated by resistance-related P-
glycoproteins. which are overexprcssed in the P388/100 
cells [ IG]. could mask the correct dctcrmination of the 
rate of diffusion of DNM into these cells. To avoid this 
j 
0 3 4 8 3 la 
Time (13.) 
Fig. 3. Kinetics of the interaction bctwbrn DNM and tirtificial lipid 
vcsiclcs with dilkrcnt surface ch;lrgc: (I) PCL: (2) neutral: (3) NCL 
liposomcs: tit pH 7.2 and 25°C. 
1- 
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possibility, the above stopped-flow experiments were 
also done in the presence of VRP, a calcium channel 
blocker able to prevent the active efflux of drugs by 
P-glycoproteins [ 171. Control experiments indicated 
that VRP at the concentration of 5 yM used in the 
assays does not perturb the fiuorescence properties of 
DNM (not shown), Fig. 4A shows the interaction of 
DNM with the P388/S and the P388/100 cells in the 
presence of VRP, a process that, similarly to what it has 
been previously observed in the absence of VRP, can be 
also described by the sum of two exponential terms such 
as those in equation 2. Under these conditions, the esti- 
mated values for the apparent rate constant of the fast 
component, k,, are similar in the P388/S and P388/100 
cells (Table 1). Although we have no explanation for a 
direct effect of VRP on the adsorption of DNM to the 
cells, it has been described that VRP may alter some of 
the properties associated to the cell surface, such as the 
membrane potential [18]. Furthermore, the presence of 
VRP consistently increases the apparent rate constant 
of the slow step, &, in the two cell lines, This effect, 
however, is much more pronounced in the P3881100 
than in the P388/S cells (Table I), suggesting that active 
drug efflux mediated by P-glycoproteins is indeed caus- 
ing an underestimation in the determination of the rare 
at which the slower component, defined by k2, occurs. 
As above, the differences in the interaction between 
DNM and P388/S or P388/100 cells in the presence of 
VRP are better visualized when the two phases are indi- 
vidually analyzed by computer (Fig. 4B and C), respec- 
tively. 
The effect of VRP on the equilibrium fluorescence 
intensity (C values) is also indicated in Table I. It is 
observed that while VRP slightly modifies the predicted 
amount of DNM associated to the P388/S obtained 
upon extrapolation, it substantially increases the extent 
of drug association to the P388/100 ceils, a finding that 
15001 
0 10 S?O 30 40 60 60 
Time (a,) 
should be expected from a resistance-reverting a ent 
[17]. Moreover. long-term uptake assays of DNM by 
the P388 cells in the presence of VRP by laser flow 
cytometry confirm, as stated by others 1191, that accu- 
mulation of DNM increases in the P388/100 but re- 
mains practically unaltered in the P388/S cells (Fig. 2B). 
4. DISCUSSrON 
In the present report we have analyzed the initial 
stages of the interaction of DNM with leukemia P388 
cells in an attempt o illustrate whether acquisition of 
resistance to anthracyclines by these cells is accompa- 
nied by alterations in the permeability to the drugs. This 
has been done by rapid kinetics which, while minimizing 
the extent of intracellular binding of DNM in the time- 
scale used in the experiments, allow the determination 
of unidirectional passive diffusion of the drug into the 
cells. 
In spite of using a very simple experimental design, 
our results reveal that the interaction between DNM 
and the P388 cells is complex and needs to be described 
by at least two kinetic components referred in the text 
as fast and slow, respectively. The fast component 
seems to involve rapid adsorption of DNM to the cell 
surface, a suggested common event shared by several 
anticancer drugs, including r/inca alkaloids and colchi- 
cinc [2,20] anthracyclines [21], etc., and presumably due 
to complex formation between phospholipids and the 
sugar residues of the drugs [22]. The differences ob- 
served in the faster component between P388/S and 
P38WlOO cells are consistent with the different surface 
environment previously reported in isolated plasma 
membrane fragments from both types of cells [I I], as 
well as with reports describing alterations in the mem- 
brane potential, which is usually decreased in MDR 
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Time (3.) 
f%& 4. Stopped-flow recordings describing the initial interaction of DNM wilh the P388 cells in the prcscrice of 5 MM VRP. Final condilions for 
DNM and ~~11 suspensions were as in Fig. I. (A) DNM Ruorcsccncc decay upon rapid interaction with the P3fWS (I) and P3881100 (3) cells. Solid 
lines WreWIl the fits of the e+crimental traces to equation 2. (I3 and C) Individualized compiler analysis of the lwo krnls. fast (B) and slow 
(12). corresponding to the interaction of DNM with the P3WS (I) and P3WlOO (1) cells, 
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membrane potential of anthracycline-resistant P388 
cells [ 181, abolishes the differences estimated in the rapid 
component between the P3WS and P388/100 cells. 
Nevertheless, the most intringuing finding arises from 
the substantial increase observed in the apparent rate 
constant of the slow component (k,) in the P388/100 
cells, upon inhibition of the active drug efflux of P- 
glycoproteins by VRP. The observation suggests that 
the slow step in the interaction of DNM with the cells 
represents a kinetic component involved in the mem- 
brane permeability to the drug. In our interpretation 
and according to our experimental design, while the 
slower kinetic component observed in the P388/S cells 
should reflect. exclusively, entrance of the drug by pas- 
sive diffusion, in the P388/100 cells, and in the presence 
of VRP it should represent he net balance from two 
opposite processes: inward passive diffusion and active 
efflux mediated by P-glycoproteins. Under these condi- 
tions, i.e. in the absence of VRP, the rates for the move- 
ment of DNM accross the plasma membranes are simi- 
lar in the P388/S and in the P388/100 cells. On the 
contrary, when the activity of P-glycoproteins is pre- 
vented by VRP, k2 would represent he ‘true’ apparent 
rate constant for passive diffusion of DNM into the 
P388/100 cells. These observations are in apparent dis- 
crepancy with previous studies reported by others 
[21,24]. Nevertheless, the considerable differences in the 
time-scale and time- resolution used previously with 
respect o those employed here makes it very difficult 
to compare the kinetic data. A comparison of the /+ 
values between the P3881S and P388/100 cells in the 
presence of VRP indicates that acquisition of resistance 
to anthracyclines by the P388 cells is accompanied by 
a considerable increase in their passive permeability to 
the drug. 
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